SCHEMBL5438474

SCHEMBL5438474

CNc1cnc2c(=O)n(C)c(=O)n(C)c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.48
LMNA P02545 3/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ALDH1A1 P00352 7/20 0.47
GAA P10253 4/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
MAPT P10636 3/20 0.45
HPGD P15428 2/20 0.44
JAK2 O60674 1/20 0.44
HTT P42858 1/20 0.44
PAX8 Q06710 1/20 0.44
ADORA2A P29274 3/20 0.42
GLA P06280 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
POLB P06746 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5448218 0.80 ALDH1A1 (0.53) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL5454832 0.77 ALDH1A1 (0.50) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL5440379 0.77 ALDH1A1 (0.54) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL5437603 0.77 ALDH1A1 (0.50) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL5438439 0.77 ALDH1A1 (0.50) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL5434474 0.74 ALDH1A1 (0.48) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL6317891 0.74 ALDH1A1 (0.47) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL5438507 0.74 KDM4E (0.56) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL6315272 0.73 ALDH1A1 (0.46) KDM4ELMNACASP1CASP7HSD17B10
SCHEMBL6316004 0.73 ALDH1A1 (0.46) KDM4ELMNACASP1CASP7HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US disclosed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
EP-1479682-A1 Immunosuppressive effects of pteridine derivatives 4 AZA Bioscience nv (BE) 2004-11-24 EP disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1686/4885LMNA 3813/4885CASP1 1804/4885
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1278/4885LMNA 3699/4885CASP1 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.